Vivos wins FDA clearance to launch Mayo Clinic feasibility study for RadioGel thyroid cancer therapy

PUBT · 1d ago
Vivos wins FDA clearance to launch Mayo Clinic feasibility study for RadioGel thyroid cancer therapy
  • Vivos received FDA clearance on July 22, 2026 for a Feasibility IDE to start a first-in-human study at Mayo Clinic in Jacksonville.
  • Initial enrollment set at 5 patients with non-resectable papillary thyroid carcinoma to assess safety and feasibility.
  • FDA shortened the required safety follow-up to 24 months from 5 years, cutting the period by about 60%.
  • Veterinary IsoPet network expanded to 17 certified US clinics, treating more than 200 small animals and horses.
  • Validation work at the Richland, Washington facility neared completion; shipments for veterinary use targeted by quarter-end.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Inc. published the original content used to generate this news brief on July 27, 2026, and is solely responsible for the information contained therein.